Cost Effectiveness of Using DPP-4i and SGLT2i Combination Therapy vs. Switching to GLP-1 Therapy for the Management of Type 2 Diabetes

被引：0
|
作者：
Pawaskar, Manjiri
Bilir, S. Pinar
Davies, Glenn M.
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-1275-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1275-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
    Anson, Matthew
    Zhao, Sizheng S.
    Austin, Philip
    Ibarburu, Gema H.
    Malik, Rayaz A.
    Alam, Uazman
    DIABETOLOGIA, 2023, 66 (10) : 1869 - 1881
  • [22] Efficacy of combination therapy with GABA, a DPP-4i and a PPI as an adjunct to insulin therapy in patients with type 1 diabetes
    Rabinovitch, Alexander
    Koshelev, Daniil
    Lagunas-Rangel, Francisco Alejandro
    Kosheleva, Liudmila
    Gavra, Tali
    Schioth, Helgi B.
    Levit, Shmuel
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [23] Cost-Effectiveness of DPP-4 Inhibitor and SGLT2 Inhibitor Combination Therapy for Type 2 Diabetes
    Pawaskar, Manjiri
    Bilir, S. Pinar
    Kowal, Stacey
    Gonzalez, Claudio
    Rajpathak, Swapnil
    Davies, Glenn
    AMERICAN JOURNAL OF MANAGED CARE, 2019, 25 (05): : 231 - +
  • [24] The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk
    Tesfaye, Helen
    Paik, Julie M.
    Alix, Caroline
    Cromer, Sara Jane
    Everett, Brendan M.
    Glynn, Robert
    Wexler, Deborah J.
    Patorno, Elisabetta
    DIABETES, 2024, 73
  • [25] The Difference in the Effects on Microalbuminuria Depending on the Order of GLP-1RA and SGLT2i Therapy in Type 2 Diabetes
    Ohara, Masaya
    Motoyama, Koka
    Tamai, Anna
    Sakura, Takeshi
    Yakushiji, Yosuke
    Hosoi, Masayuki
    DIABETES, 2019, 68
  • [26] The Risk of Major CV Events after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-toModerate CV Risk
    Patorno, Elisabetta
    Tesfaye, Helen
    Alix, Caroline
    Dicesare, Elyse C.
    Cromer, Sara Jane
    Everett, Brendan M.
    Glynn, Robert
    Wexler, Deborah J.
    Paik, Julie M.
    DIABETES, 2024, 73
  • [27] Predictors of Selection of a GLP1RA vs. SGLT2i in People with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    Agarwal, Shubham
    Basit, Mujeeb A.
    Bowen, Michael E.
    Heitjan, Daniel
    Mai, Christine
    Marble, Kelsea
    Xiang, Zichang
    Lingvay, Ildiko
    DIABETES, 2024, 73
  • [28] Network Meta-analysis of DPP-4i/SGLT2i Combination as Add-on to Metformin for T2DM
    Orme, Michelle Elaine
    Qin, Lei
    Varol, Nebibe
    Bell, Kelly
    Mukherjee, Jayanti
    DIABETES, 2016, 65 : A296 - A296
  • [29] Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity
    Terenzi, Daniella C.
    Bakbak, Ehab
    Teoh, Hwee
    Krishnaraj, Aishwarya
    Puar, Pankaj
    Rotstein, Ori D.
    Cosentino, Francesco
    Goldenberg, Ronald M.
    Verma, Subodh
    Hess, David A.
    CARDIOVASCULAR RESEARCH, 2024, 119 (18) : 2858 - 2874
  • [30] GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes
    Huang, Tao
    Bosi, Alessandro
    Faucon, Anne-Laure
    Grams, Morgan E.
    Sjolander, Arvid
    Fu, Edouard L.
    Xu, Yang
    Carrero, Juan Jesus
    JAMA INTERNAL MEDICINE, 2024, 184 (10) : 1195 - 1203
12345